Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open weighing Clear all
Recruiting Phase 3 Interventional

A Long-Term Study of JNT-517 in Participants With Phenylketonuria

NCT06628128
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
JNT-517
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Gainesville, Florida • Tampa, Florida • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 17, 2026, 8:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab Subcutaneous, Guselkumab Intravenous
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

NCT03601637
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months to 23 Months
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

NCT01166412
View directory record Official record
Conditions
Contraception
Interventions
levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2, levonorgestrel patch with BMI <32 kg/m2
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Aurora, Colorado • New York, New York • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

NCT03759366
View directory record Official record
Conditions
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 17, 2026, 8:22 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

NCT00473824
View directory record Official record
Conditions
Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
Interventions
Hepatitis C Immune Globulin Intravenous (Human) 5%
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Remdesivir in Participants Below 18 Years Old With COVID-19

NCT04431453
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Expansion of the Weigh Smart Pediatric Group Family Oriented Weight Management Program Through the Use of Telehealth

NCT04521595
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Weigh Smart Telehealth intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

NCT00549939
View directory record Official record
Conditions
Neurogenic Urinary Bladder
Interventions
Alfuzosin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 16 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 17, 2026, 8:22 AM EDT
Terminated Phase 1 Interventional

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

NCT02368951
View directory record Official record
Conditions
Medical Oncology
Interventions
BAY1187982
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Francisco, California • Santa Monica, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 17, 2026, 8:22 AM EDT
Terminated Not applicable Interventional Results available

Cerebrospinal Fluid Pharmacokinetics of Daptomycin

NCT01025271
View directory record Official record
Conditions
Meningitis
Interventions
Daptomycin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 17, 2026, 8:22 AM EDT
Active, not recruiting Phase 1 Interventional

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

NCT04170153
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
M1774, Niraparib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Austin, Texas • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 17, 2026, 8:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

NCT00048542
View directory record Official record
Conditions
Arthritis, Juvenile Idiopathic
Interventions
Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
4 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

NCT01603641
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 17 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Pasadena, California • Pomona, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 17, 2026, 8:22 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

NCT02600351
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
38
States / cities
Little Rock, Arkansas • Los Angeles, California • Pasadena, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
View directory record Official record
Conditions
Dialysis, Anemia
Interventions
Roxadustat, Oral Iron, IV Iron
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Northridge, California • Yuba City, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

NCT01594957
View directory record Official record
Conditions
Hepatic Impairment
Interventions
LCQ908
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 17, 2026, 8:22 AM EDT
Completed No phase listed Observational

Laparoscopic Revision of Vertical Banded Gastroplasty to Gastric Bypass

NCT01041131
View directory record Official record
Conditions
Clinically Severe Obesity, Inadequate Weight Loss, Obesity Recidivism
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

NCT04123795
View directory record Official record
Conditions
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Interventions
Certolizumab pegol, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
6 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

NCT00891839
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
11
States / cities
Fountain Valley, California • Los Angeles, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 17, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

NCT01701401
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 17, 2026, 8:22 AM EDT
Recruiting Phase 3 Interventional

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 17, 2026, 8:22 AM EDT